Tempest Therapeutics is charting rocky waters as it looks to secure a partner to advance its liver cancer drug through a Phase III trial.
The US biotech’s clinical asset, amezalpat, has already demonstrated positive Phase II data, though the step to Phase III looks more difficult.
Go deeper with GlobalData
“The capital markets have been unavailable to support the next stage of development,” Tempest’s CEO Stephen Brady said in a statement.
The company is looking at “strategic alternatives”, which could include a merger, acquisition, or partnership. Joint ventures, licensing arrangements, and other transaction types are also on the table.
Brady added that the options “include finding a strategic partner with the resources to develop what we believe are potentially life-saving therapies for patients in need”.
Tempest made the announcement after market close on 9 April after its Nasdaq-listed shares closed 10.7% higher, in part due to a stock split executed by Tempest on the same day. The biotech has a market cap of $25.1m.
Investment in biotech and biopharma has been at an all-time low since the 2021 boom. This has made it difficult for companies to advance therapies through trials without seeking alternative funding methods.
Amezalpat, dubbed TPST-1120, has the US Food and Drug Administration (FDA) go-ahead for a pivotal Phase III trial (NCT06680258). The orally administered drug will be evaluated in combination with Roche’s Tecentriq (atezolizumab) and Genentech’s Avastin (bevacizumab) in unresectable or metastatic hepatocellular carcinoma (HCC).
Tempest secured the services of Roche to supply Tecentriq for the planned trial via an October 2024 partnership. The two companies were already collaborating on a Phase I/II umbrella study (NCT04524871) evaluating amezalpat in combination with Tecentriq and Avastin in first-line HCC patients and compared to Tecentriq and Avastin alone. Amezalpat demonstrated a six-month improvement in median overall survival (OS) for patients receiving the combination therapy, in comparison to the control arm of Roche’s and Genentech’s treatments alone.
Amezalpat is a peroxisome proliferator-activated receptor alpha (PPAR⍺) antagonist. PPAR⍺ is a nuclear receptor involved in lipid metabolism pathways, though growing evidence suggests it can also modulate carcinogenesis.
Despite growing competition in the liver cancer treatment space, revenue for drugs remains high. Tecentriq generated sales of $2.14bn for Roche in 2024, making it one of the big pharma’s top-selling drugs. Tempest believes that amezalpat can join the high-revenue party, stating that it holds blockbuster potential in first-line HCC.
There are no PPAR⍺ antagonists currently approved by the FDA. The agency has noted the drug’s promise, granting it fast track designation and orphan drug designation for the treatment of HCC.
Tempest’s pipeline also includes a dual EP2/4 prostaglandin receptor antagonist named TPST-1495. The biotech is also seeking the same strategic partnerships for a Phase II study of this asset. TPST-1495 has FDA orphan drug designation for the treatment of familial adenomatous polyposis (FAP).
Tempest ended the 2024 fiscal year with $30.3m in cash, down from $39.2m at the end of 2023. Loss for the biotech increased from $29.5m in 2023 to $41.8m in 2024.
